Crossref
Alzheimer’s drug approval gets a mixed reception
Science · 2023
DOI: 10.1126/science.adg6275 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science, 2023. Verfasst von Jennifer Couzin-Frankel. Hauptthemen laut MEDLINE: Alzheimer Disease, Antibodies, Monoclonal, Humanized, Drug Approval. Die Arbeit wurde bisher 8-mal zitiert (Crossref).
Themen: Demenz
Abstract (Originalsprache)
FDA allows use of antibody despite ongoing debates over its benefits and dangers
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Alzheimer DiseaseAntibodies, Monoclonal, HumanizedDrug ApprovalHumansUnited StatesUnited States Food and Drug Administration
Substanzen
Antibodies, Monoclonal, Humanizedlecanemab
Zitieren
APA
Couzin-Frankel, J. (2023). Alzheimer’s drug approval gets a mixed reception. Science. https://doi.org/10.1126/science.adg6275
Vancouver
Couzin-Frankel J. Alzheimer’s drug approval gets a mixed reception. Science. 2023. doi:10.1126/science.adg6275
BibTeX
@article{CouzinFrankel2023,
author = {Couzin-Frankel, Jennifer},
title = {Alzheimer’s drug approval gets a mixed reception},
journal = {Science},
year = {2023},
doi = {10.1126/science.adg6275}
}
EUVIMED